Jarrett R. Remsberg

Jarrett R. Remsberg

Auto-generated profile, based on publicly available information

Jarrett R. Remsberg

Department of Chemistry and The Skaggs Institute for Chemical Biology The Scripps Research Institute 10550N. Torrey Pines Road La Jolla CA-92307 USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2019 in Nature Chemistry
Verified
Journal Article
Closed access
YWYujia Wang
Yujia Wang
MDMelissa M. Dix
Melissa M. Dix
GBGiulia Bianco
Giulia Bianco
JRJarrett R. Remsberg
Jarrett R. Remsberg
HLHsin-Yu Lee
Hsin-Yu Lee
BCBenjamin F. Cravatt
Benjamin F. Cravatt

29 April 2021 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
JRJarrett R. Remsberg
Jarrett R. Remsberg
RSRadu M. Suciu
Radu M. Suciu
NZNoemi A. Zambetti
Noemi A. Zambetti
THThomas W. Hanigan
Thomas W. Hanigan
AFAri J. Firestone
Ari J. Firestone
BCBenjamin F. Cravatt
Benjamin F. Cravatt

2 March 2023 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
SKStefan G. Kathman
Stefan G. Kathman
SKSeong Joo Koo
Seong Joo Koo
GLGarrett L. Lindsey
Garrett L. Lindsey
HHHsuan-Lin Her
Hsuan-Lin Her
SBSteven M. Blue
Steven M. Blue
BCBenjamin F. Cravatt
Benjamin F. Cravatt

14 November 2023 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
YTYongfeng Tao
Yongfeng Tao
JFJan G. Felber
Jan G. Felber
ZZZhongyu Zou
Zhongyu Zou
ENEvert Njomen
Evert Njomen
JRJarrett R. Remsberg
Jarrett R. Remsberg
BCBenjamin F. Cravatt
Benjamin F. Cravatt
5‐Methylcytosine (m5C) is an RNA modification prevalent on tRNAs, where it can protect tRNAs from endonucleolytic cleavage to maintain protein synthesis. The NSUN family (NSUN1‐7 in humans) of RNA methyltransferases are capable of installing the methyl group onto the C5 position of cytosines in RNA. NSUNs are implicated in a wide range of (patho)physiological processes, but selective and cell‐active inhibitors of these enzymes are lacking. Here, we use cysteine‐directed activity‐based protein profiling (ABPP) to discover azetidine acrylamides that act as stereoselective covalent inhibitors of human NSUN2. Despite targeting a conserved catalytic cysteine in the NSUN family, the NSUN2 inhibitors show negligible cross‐reactivity with other human NSUNs and exhibit good proteome‐wide selectivity. We verify that the azetidine acrylamides inhibit the catalytic activity of recombinant NSUN2, but not NSUN6, and demonstrate that these compounds stereoselectively disrupt NSUN2‐tRNA interactions in cancer cells, leading to a global reduction in tRNA m5C content. Our findings thus highlight the potential to create isotype‐selective and cell‐active inhibitors of NSUN2 with covalent chemistry targeting a conserved catalytic cysteine.

2 October 2023 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
HLHaoxin Li
Haoxin Li
TMTiantai Ma
Tiantai Ma
JRJarrett R. Remsberg
Jarrett R. Remsberg
SWSang Joon Won
Sang Joon Won
KDKristen E. DeMeester
Kristen E. DeMeester
BCBenjamin F. Cravatt
Benjamin F. Cravatt

14 May 2020 in Blood
Verified
Journal Article
Open access
PDF file
NZNoemi A. Zambetti
Noemi A. Zambetti
AFAri J. Firestone
Ari J. Firestone
JRJarrett R. Remsberg
Jarrett R. Remsberg
BHBenjamin J. Huang
Benjamin J. Huang
JWJasmine C. Wong
Jasmine C. Wong
KSKevin Shannon
Kevin Shannon
Oncogenic RAS mutations pose substantial challenges for rational drug discovery. Sequence variations within the hypervariable region of Ras isoforms underlie differential posttranslational modification and subcellular trafficking, potentially resulting in selective vulnerabilities. Specifically, inhibiting the palmitoylation/depalmitoylation cycle is an appealing strategy for treating NRAS mutant cancers, particularly as normal tissues would retain K-Ras4b function for physiologic signaling. The role of endogenous N-RasG12D palmitoylation in signal transduction, hematopoietic differentiation, and myeloid transformation is unknown, and addressing these key questions will inform efforts to develop mechanism-based therapies. To evaluate the palmitoylation/depalmitoylation cycle as a candidate drug target in an in vivo disease-relevant model system, we introduced a C181S mutation into a conditional NrasG12D “knock-in” allele. The C181S second-site amino acid substitution abrogated myeloid transformation by NrasG12D, which was associated with mislocalization of the nonpalmitoylated N-Ras mutant protein, reduced Raf/MEK/ERK signaling, and alterations in hematopoietic stem and progenitor populations. Furthermore, hematologic malignancies arising in NrasG12D/G12D,C181S compound heterozygous mice invariably acquired revertant mutations that restored cysteine 181. Together, these studies validate the palmitoylation cycle as a promising therapeutic target in NRAS mutant cancers.